EXACT Therapeutics AS Board Update

OSLO/LONDON, 19 May 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, today announces that its Board Member, Dr. Jean-Claude Provost will step down with immediate effect.

Dr. Provost has taken on a new role as interim CMO of Lantheus Holdings (NASDAQ: LNTH). As this could represent a conflict of interest with his current Board appointment to EXACT-Tx, the Company and Dr. Provost have agreed that he will resign from the Board of Directors with immediate effect. The Nomination Committee is recommending that he is not replaced at the AGM in June.

On behalf of the shareholders, the Board thanks Dr. Provost for his support and contribution to EXACT-Tx over the last few years.

ENDS

For more information, please contact: 

Masha Strømme, Executive Chair
Exact Therapeutics
Email: Masha@exact-tx.com

Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.

Previous
Previous

EXACT Therapeutics AS - Notice of Annual General Meeting 2022

Next
Next

EXACT Therapeutics AS announces start date of 06/06/2022 for its new CEO Per Walday, relocation of some activities to Oslo and Dominic Moreland stepping down as CFO